Stephens Downgrades Exact Sciences (EXAS) to Equal Weight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- Meta Platforms stock surges 8% on cloud business plans
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Wall Street ends choppy session lower as tech shares drop
Jefferies Cuts Price Target on Exact Sciences (EXAS) Following Disappointing Outlook
February 25, 2016 9:29 AM ESTJefferies maintained a Buy rating on Exact Sciences (NASDAQ: EXAS), and cut the price target to $13.00 (from $15.00), following the company's 4Q. . In light of the 4Q test volume shortfall, EXAS' initial outlook for flattish trends in 1Q16 was disappointing. EXAS reaffirmed its '16 revenue... More
Roth Capital Downgrades Exact Sciences (EXAS) to Neutral
February 25, 2016 6:56 AM ESTRoth Capital downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Neutral.
For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.
Shares of Exact Sciences closed at $5.87 yesterday.
... MoreCraig-Hallum Downgrades Exact Sciences (EXAS) to Hold
February 24, 2016 1:37 PM ESTCraig-Hallum downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Hold.
For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.
Shares of Exact Sciences closed at $6.41 yesterday.
... MoreExact Sciences (EXAS) Tops Q4 EPS by 6c, Maintains Cologuard Outlook
February 24, 2016 7:31 AM ESTExact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($0.41), $0.06 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $14.4 million versus the consensus estimate of $14.82 million.
2016 Outlook
The company continues to anticipate completing more than 240,000 Cologuard tests during 2016, generating between... More
